U.S. markets closed

Orchard Therapeutics plc (ORTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.0500-0.0900 (-7.89%)
At close: 04:00PM EST
1.0700 +0.02 (+1.90%)
After hours: 05:48PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.1400
Bid1.0500 x 1100
Ask1.0900 x 2200
Day's Range1.0400 - 1.1400
52 Week Range1.0400 - 9.0800
Avg. Volume1,011,770
Market Cap131.774M
Beta (5Y Monthly)1.11
PE Ratio (TTM)N/A
EPS (TTM)-1.2120
Earnings DateFeb 28, 2022 - Mar 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.79
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ORTX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Orchard Therapeutics plc
    Daily – Vickers Top Buyers & Sellers for 09/09/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • GlobeNewswire

    Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones

    Launch Momentum Building for Libmeldy® in Europe with Health Technology Assessments Progressing Favorably and Treatment Underway for Multiple Commercial Patients Initiating U.S. BLA Submission for OTL-200 as Early as Year End 2022; Constructive CMC Meeting with FDA Supports Timeline EU MAA Submission for OTL-103 in Wiskott-Aldrich Syndrome Expected in Mid-2022 Following Productive Regulatory Interactions Ended 2021 with approximately $220M in Cash and Investments to Support Operations into the F

  • GlobeNewswire

    Orchard Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

    BOSTON and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday January 13, 2022, at 9:00 a.m. ET. A live webcast of the presentation and breakout session will be available under "News & Events" in the Investors & Media section of the company's website at Webcast replays will be archived on th

  • GlobeNewswire

    Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome

    100 percent overall survival with median follow-up of two years post-treatment with HSC gene therapy Preliminary findings show promising metabolic and early clinical outcomes Results warrant further evaluation in global registrational study expected to be initiated in 2022 following recent meeting to discuss trial design with U.S. and European regulators BOSTON and LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced data pu